|  | PK/PD 
      - General Concepts and Advanced Material - ADVANCED LEVEL | 
| PK/PD Modeling Methods and Clinical Applications (Intermediate - Advanced - Expert Level) |  | 
| Faculty: Roger Jelliffe, MD | 
|  Target 
        Participants:This 
      workshop, using minimal math, starts at a beginning level and progresses 
      to an advanced level over 2 intensive days. It is intended for physicians, 
      pharmacists, clinical chemists and biomedical scientists who have an interest 
      in clinical therapeutic drug monitoring and optimal individualization of 
      drug therapy for patient care and in population pharmacokinetic and pharmacodynamic 
      research modeling techniques. Participants will be introduced to the USC*PACK 
      software which can be used both for therapeutic drug monitoring as well 
      as for parametric and nonparametric population PK/PD and physiological modeling. | 
| Objectives and Expectations: After this workshop, the participant should: | 
| 1. | Be able 
      to describe basic pharmacokinetic behavior of drugs in patients. | 
| 2. | Be able to design optimal initial individualized dosage regimens of drugs to hit selected target goals most precisely. | 
| 3. | Be able to enter and store patient data of doses, TDM serum concentrations, etc., and to make an individualized model of drug behavior in that patient. | 
| 4. | Be able to develop an adjusted dosage regimen based on the patient's individualized model. | 
| 5. | Understand how to apply these techniques to therapy with vancomycin, digoxin, anticonvulsants, and drugs for AIDS, cancer, and transplants. | 
| 6. | Understand the basic ideas (not the math) behind parametric and nonparametric population PK/PD modeling. | 
| 7. | Know how to determine the error polynomial for a drug assay, to fit each data point by an optimal measure of its credibility. | 
| 8. | Understand Monte-Carlo simulation and its applications to clinical situations. | 
| 9. | Understand the basic concepts of multiple model dosage design. | 
| PK/PD Modeling Methods and Clinical Applications (Intermediate - Advanced - Expert Level) | Tuesday, 
         September 07th, 2004 | 
Preliminary Program
| Time | Topic | 
| 8:30 | Beginning-Intermediate 
        Clinical PK 1The basic PK model – Roger Jelliffe Dose individualization using target concentration 
        strategy                     An 
        example for discussion: tracking drug behavior in unstable patients, with Basic PK building blocks                     
        Evaluating renal function, especially in unstable patients | 
| 9:30 | Beginning-Intermediate Clinical PK 2Ways of fitting data - Roger Jelliffe | 
| 10:30 | Coffee | 
| 11:00 | Beginning-Intermediate 
        Population Modeling           
             Parametric, iterative 2 stage Bayesian (IT2B) population modeling - Roger Jelliffe | 
| 11:45 | Nonparametric Population Modeling - Roger JelliffeIts 
        strengths and weaknesses | 
| 12:30 | Multiple 
        Model Dosage Design - Roger Jelliffe | 
| 13:00 | Lunch | 
| 14:30 | Intermediate PK – Tissue Distribution                  Modeling diffusion in endocardial vegetations - Roger Jelliffe | 
| 15:30 | How to describe and build PD relationships for anti-infective 
        drugs - George Drusano | 
| 16:00 | Erythropoetin therapy in childhood renal anemia - Rüdiger Port | 
| 16:30 | End | 
| PK/PD Modeling Methods and Clinical Applications (Intermediate - Advanced - Expert Level) | Wednesday, 
         September 08th, 2004 | 
Preliminary Program
| Time | Topic | 
| 8:30 | Advanced 
        PK 3Modeling 
        linear and nonlinear antiepileptic drug  models - Irina Bondareva | 
| 9:00 | Outcome and costs 
        of a goal-oriented, model-based, active TDM service – Alexander Vinks | 
| 9:45 | Combination chemotherapy 
        - Monte-Carlo simulation: from PK/PD                
        Relationships to clinical applications - George Drusano | 
| 10:30 | Coffee | 
| 11:00 | Applied Clinical 
        PK 4 Getting Nonparametric 
        Bayesian Posteriors – Roger 
        Jelliffe The structure of MM Bayesian dosage 
        individualization and adjustment | 
| 12:00 | Aminoglycoside ototoxicity - 
        Roger Jelliffe | 
| 12:30 | Introduction 
        to Clinical Cases - Roger Jelliffe        
            Planning initial MM aminoglycoside 
        therapy | 
| 13:00 | Lunch | 
| 14:30 | Advanced Clinical 
        PK 5 More clinical case 
        histories - Roger Jelliffe | 
| 16:30 | End | 
Link to the PK/PD General Concepts program at the beginner - intermediate level